Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Nat Immunol ; 24(8): 1345-1357, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37400675

RESUMEN

CD4+ T cells play key roles in a range of immune responses, either as direct effectors or through accessory cells, including CD8+ T lymphocytes. In cancer, neoantigen (NeoAg)-specific CD8+ T cells capable of direct tumor recognition have been extensively studied, whereas the role of NeoAg-specific CD4+ T cells is less well understood. We have characterized the murine CD4+ T cell response against a validated NeoAg (CLTCH129>Q) expressed by the MHC-II-deficient squamous cell carcinoma tumor model (SCC VII) at the level of single T cell receptor (TCR) clonotypes and in the setting of adoptive immunotherapy. We find that the natural CLTCH129>Q-specific repertoire is diverse and contains TCRs with distinct avidities as measured by tetramer-binding assays and CD4 dependence. Despite these differences, CD4+ T cells expressing high or moderate avidity TCRs undergo comparable in vivo proliferation to cross-presented antigen from growing tumors and drive similar levels of therapeutic immunity that is dependent on CD8+ T cells and CD40L signaling. Adoptive cellular therapy (ACT) with NeoAg-specific CD4+ T cells is most effective when TCR-engineered cells are differentiated ex vivo with IL-7 and IL-15 rather than IL-2 and this was associated with both increased expansion as well as the acquisition and stable maintenance of a T stem cell memory (TSCM)-like phenotype in tumor-draining lymph nodes (tdLNs). ACT with TSCM-like CD4+ T cells results in lower PD-1 expression by CD8+ T cells in the tumor microenvironment and an increased frequency of PD-1+CD8+ T cells in tdLNs. These findings illuminate the role of NeoAg-specific CD4+ T cells in mediating antitumor immunity via providing help to CD8+ T cells and highlight their therapeutic potential in ACT.


Asunto(s)
Linfocitos T CD8-positivos , Neoplasias , Ratones , Animales , Receptor de Muerte Celular Programada 1/metabolismo , Neoplasias/metabolismo , Receptores de Antígenos de Linfocitos T/metabolismo , Inmunoterapia Adoptiva , Inmunoterapia , Linfocitos T CD4-Positivos , Células Madre , Microambiente Tumoral
3.
Cell Rep ; 31(1): 107249, 2020 04 07.
Artículo en Inglés | MEDLINE | ID: mdl-32268093

RESUMEN

CD4+ T lymphocytes are crucial for controlling a range of innate and adaptive immune effectors. For CD8+ cytotoxic T lymphocyte (CTL) responses, CD4+ T cells can function as helpers (TH) to amplify magnitude and functionality or as regulatory cells (Treg) capable of profound inhibition. It is unclear what determines differentiation to these phenotypes and whether pathogens provoke alternate programs. We find that, depending on the size of initial dose, Listeria infection drives CD4+ T cells to act as TH or induces rapid polyclonal conversion to immunosuppressive Treg. Conversion to Treg depends on the TLR9 and IL-12 pathways elicited by CD8α+ dendritic cell (DC) sensing of danger-associated neutrophil self-DNA. These findings resolve long-standing questions regarding the conditional requirement for TH amongst pathogens and reveal a remarkable degree of plasticity in the function of CD4+ T cells, which can be quickly converted to Tregin vivo by infection-mediated immune modulation.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , ADN/inmunología , Listeriosis/inmunología , Linfocitos T Reguladores/inmunología , Receptor Toll-Like 9/inmunología , Animales , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD8-positivos/inmunología , Diferenciación Celular/inmunología , ADN/genética , Células Dendríticas/inmunología , Femenino , Inmunidad Celular/efectos de los fármacos , Inmunidad Celular/genética , Inmunidad Celular/inmunología , Interleucina-12/biosíntesis , Interleucina-12/genética , Interleucina-12/inmunología , Listeria monocytogenes/inmunología , Listeriosis/genética , Activación de Linfocitos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Transducción de Señal/inmunología , Linfocitos T Citotóxicos/inmunología , Linfocitos T Colaboradores-Inductores/inmunología , Receptor Toll-Like 9/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...